Validation of the normal, freely moving Göttingen minipig for pharmacological safety testing

Journal of Pharmacological and Toxicological Methods

Volumn 60, Issue 1, 2009, Pages 79-87

  Markert, Michael ^a   Stubhan, Miriam ^a   Mayer, Karin ^a   Trautmann, Thomas ^a   Klumpp, Anja ^a   Schuler Metz, Annette ^a   Schumacher, Kurt ^a   Guth, Brian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Arterial blood pressure; Conscious minipig; Contractility; Heart rate; Hemodynamic; Methods; QT duration; Telemetry

Indexed keywords

MOXIFLOXACIN; PLACEBO; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; BODY TEMPERATURE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART RATE; MALE; MINIPIG; NONHUMAN; QT INTERVAL; QT PROLONGATION; TELEMETRY; VALIDATION PROCESS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AZA COMPOUNDS; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART RATE; HEMODYNAMICS; MALE; MODELS, ANIMAL; PROPRANOLOL; QUINOLINES; SWINE; SWINE, MINIATURE; TELEMETRY;

ANIMALIA; SUIDAE;

EID: 68549117109     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.12.004     Document Type: Article

References (19)

1. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?. Journal of Electrocardiology 37 SUPPL. (2004) 15-24
2. Balfour J.A.B., and Wiseman L.R. Moxifloxacin. Drugs 3 (1999) 363-374
3. Clozel J.P., Danchin N., Genton P., Thomas J.L., and Cherrier F. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism. Clinical Pharmacology and Therapeutics 36 1 (1984) 64-69
4. Demolis J.L., Kubitza D., Tenneze L., and Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clinical Pharmacology and Therapeutics 68 (2000) 658-666
5. Fermini B., and Fossa A.A. Pre-clinical assessment of drug-induced QT interval prolongation. Current issues and impact on drug discovery. Annual Reports in Medicinal Chemistry 39 (2004) 323-334
6. Guth B.D., Germeyer S., Kolb W., and Markert M. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. Journal of Pharmacological and Toxicological Methods 49 3 (2004) 159-169
7. ICH. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B) (2005)
8. Kano M., Toyoshi T., Iwasaki S., Dato M., Shimizu M., and Ota T. QT PRODACT: Usability of miniature pigs in safety pharmacology studies: Assessment for drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 5 (2005) 501-511
9. Klumpp A., Trautmann T., Markert M., and Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological and Toxicological Methods 54 2 (2006) 141-149
10. Lalonde R.L., Pieper J.A., Straka R.J., Bottorff M.B., and Mirvis D.M. Propranolol pharmacokinetics and pharmacodynamics after single dose and at steady state. European Journal of Clinical Pharmacology 33 (1987) 315-318
11. Markert M., Klumpp A., Trautmann T., and Guth B. A novel propellant-free inhalation drug delivery system for cardiovascular drug safety evaluation in conscious dogs. Journal of Pharmacological and Toxicological Methods 50 2 (2004) 109-119
12. Markert M., Klumpp A., Trautmann T., Mayer K., Stubhan M., and Guth B. The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. Journal of Pharmacological and Toxicological Methods 56 2 (2007) 203-211
13. Meyners M., and Markert M. Correcting the QT interval for changes in HR in pre-clinical drug development. Methods of Information in Medicine 43 (2004) 445-450
14. Pugsley M.K., and Curtis M.J. Safety pharmacology in focus: New methods developed in the light of the ICH S7B guidance document. Journal of Pharmacological and Toxicological Methods 54 2 (2006) 94-98
15. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., and Wallis R. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 1 (2003) 32-45
16. Shah R. Drugs, QT interval prolongation and ICH E14: The need to get it right. Drug Safety 28 2 (2005) 115-125
17. Stubhan M., Markert M., Mayer K., Trautmann T., Klumpp A., Henke J., and Guth B. Evaluation of cardiovascular and ECG parameters in the normal, freely moving Göttingen minipig. Journal of Pharmacological and Toxicological Methods 57 (2008) 2002-2211
18. Sundaram S., Carnethon M., Polito K., Kadish H., and Jeffrey J. Autonomic effects on QT-RR interval dynamics after exercise. American Journal of Physiology Heart and Circulatory Physiology 294 (2008) H490-H497
19. Zabel M., Woosley R.L., and Franz M.R. Is dispersion of ventricular repolarization rate dependent?. PACE - Pacing and Clinical Electrophysiology 20 10 I (1997) 2405-2411